Diminished platelet residence time on active human atherosclerotic lesions in-vivo--evidence for an optimal dose of aspirin?
Although aspirin is an old drug, its optimal dose for the treatment of human atherosclerosis has not been finally proven. Various in-vitro and ex-vivo platelet function tests revealed a dose range from 1 to 3000 mg as being optimal. It was thus the goal to examine its in-vivo efficacy in human suffering from peripheral vascular disease in 7 different doses ranging from 1 mg to 1000 mg a day. All these patients have been treated for 3 months. Platelet half-life and platelet uptake ratio show an in part significant improvement being most pronounced at the daily doses of 20 and 1000 mg respectively. No change occurs in the placebo treated controls. These findings indicate, that 20 or 1000 mg aspirin taken daily per os, are superior to the other doses examined concerning the in-vivo platelet function (as measured by platelet half-life) and rendering the arterial surface less thrombogenic (as reflected by platelet uptake ratio-measurements).
Sinzinger
H
H
Dept. of Nuclear Medicine, University of Vienna, Austria.
Kaliman
J
J
Fitscha
P
P
O'Grady
J
J
D000284:Administration, Oral; D000368:Aged; D001161:Arteriosclerosis / Q000188:drug therapy*; D001241:Aspirin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001792:Blood Platelets / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D013929:Thromboxane B2 / Q000097:blood; D013997:Time Factors
D013929:Thromboxane B2; D001241:Aspirin